The Effects of Systemic Lupus Erythematous on Myocardial Infarctions
DOI:
https://doi.org/10.25255/jss.2025.14.1.1.23Keywords:
Systemic Lupus Erythematosus, Myocardial Infarctions, Disease Susceptibility, Heart diseasesAbstract
Hypothesis: Patients with systemic lupus erythematosus are more susceptible to myocardial infarctions than unaffected individuals.
Methods: This paper study analyzed were carried out for ten papers obtained from several database platforms. The database platforms considered include; Cureus Journal of Medical Science, Google scholar, PubMed, British Medical Journal (BMJ), and National Centre for Biotechnology Information (NCBI) were analyzed. keywords such as (Myocardial Infarctions), (myocardial infarction) AND (Systemic lupus erythematosus) were used to search for articles. Additionally, papers of interest included Cohort study, Randomized Control Trials (RCTs), and Cross-sectional studies with the target study population. Only articles viewable as full text were included.
Results: A total of ten quantitative articles that fell within the specific parameters were selected, of which eight studies were Cohort, two Randomized Control Trials, and one Cross-sectional. The findings pointed out that many parameters play an influencing role in increasing the odds of having myocardial infarctions MI. Nevertheless, most of the included papers directly inferred the existence of a demonstrated effect of Systemic Lupus Erythematosus (SLE) on increasing the susceptibility to having myocardial infarctions.
Conclusion: The findings supported the reviews’ hypothesis, indicating a positive correlation between SLE and MI in patients. That is, SLE is a natural and significant factor affecting MI occurrences.
Downloads
References
Ajeganova, S., Hafström, I., & Frostegård, J. (2021). Patients with SLE have a higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and anti-phospholipid syndrome: a case-control study over 10 years. Lupus Science & Medicine, 8(1), e000454. https://doi.org/10.1136/lupus-2020-000454
Ajeganova, S., Hafström, I., & Frostegåd, J. (2020). P160 Risk of CV events and mortality in SLE is associated with accumulated disease-damage, anti-phospholipid syndrome, and higher carotid intima-media thickness. https://doi: 10.1136/lupus-2020-eurolupus.202
Artola, R. T., Mihos, C. G., & Santana, O. (2016). Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus. Southern medical journal, 109(11), 705–711. https://doi.org/10.14423/SMJ.0000000000000561
Aviña-Zubieta, J. A., To, F., Vostretsova, K., De Vera, M., Sayre, E. C., & Esdaile, J. M. (2017). Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. Arthritis Care & Research, 69(6), 849–856. https://doi.org/10.1002/acr.23018
Bhatnagar, P., Wickramasinghe, K., Wilkins, E., & Townsend, N. (2016). Trends in the epidemiology of cardiovascular disease in the UK. Heart, 102(24), 1945–1952. https://doi.org/10.1136/heartjnl-2016-309573
Chen, S. K., Barbhaiya, M., Fischer, M. A., Guan, H., Yoshida, K., Feldman, C. H., Costenbader, K. H., & Everett, B. M. (2019). Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, 49(3), 389–395. https://doi.org/10.1016/j.semarthrit.2019.06.005
Chin, C. W. L., Chin, C.-Y., Ng, M. X. R., Le, T.-T., Huang, F.-Q., Fong, K.-Y., Thumboo, J., & Tan, R.-S. (2014). Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. Rheumatology International, 34(9), 1281–1285. https://doi.org/10.1007/s00296-014-2968-4
Farooq, A., Ullah, A., Ali, F., Yasin, H., Amjad, W., & Pervaiz, M. (2017). Acute Myocardial Infarction in Young Systemic Lupus Erythematosus Patient with Normal Coronary Arteries. Cureus. https://doi.org/10.7759/cureus.1370
Fernández-Nebro, A., Rúa-Figueroa, Í., López-Longo, F. J., Galindo-Izquierdo, M., Calvo-Alén, J., Olivé-Marqués, A., Ordóñez-Cañizares, C., Martín-Martínez, M. A., Blanco, R., Melero-González, R., Ibáñez-Rúan, J., Bernal-Vidal, J. A., Tomero-Muriel, E., Uriarte-Isacelaya, E., Horcada-Rubio, L., Freire-González, M., Narváez, J., Boteanu, A. L., Santos-Soler, G., & Andreu, J. L. (2015). Cardiovascular Events in Systemic Lupus Erythematosus. Medicine, 94(29), e1183. https://doi.org/10.1097/md.0000000000001183
Gaipl, U. S., Munoz, L. E., Grossmayer, G., Lauber, K., Franz, S., Sarter, K., Voll, R. E., Winkler, T., Kuhn, A., Kalden, J., Kern, P., & Herrmann, M. (2007). Clearance deficiency and systemic lupus erythematosus (SLE). Journal of Autoimmunity, 28(2-3), 114–121. https://doi.org/10.1016/j.jaut.2007.02.005
Gustafsson, J. T., Herlitz Lindberg, M., Gunnarsson, I., Pettersson, S., Elvin, K., Öhrvik, J., Larsson, A., Jensen-Urstad, K., & Svenungsson, E. (2017). Excess atherosclerosis in systemic lupus erythematosus, A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLOS ONE, 12(4), e0174572. https://doi.org/10.1371/journal.pone.0174572
Holmqvist, M., Simard, J. F., Asplund, K., & Arkema, E. V. (2015). Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open, 1(1), e000168. https://doi.org/10.1136/rmdopen-2015-000168
Krittanawong, C., Luo, Y., Mahtta, D., Narasimhan, B., Wang, Z., Jneid, H., Tamis-Holland, J. E., Mahboob, A., Baber, U., Mehran, R., Wilson Tang, W. H., Ballantyne, C. M., & Virani, S. S. (2020). Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. IJC Heart & Vasculature, 30, 100634. https://doi.org/10.1016/j.ijcha.2020.100634
Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., Gillespie, C., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, P. M., Howard, V., Kissela, B., Kittner, S., Lackland, D., & Lisabeth, L. (2010). Executive Summary: Heart Disease and Stroke Statistics—2010 Update. Circulation, 121(7), 948–954. https://doi.org/10.1161/circulationaha.109.192666
Lu, L., Liu, M., Sun, R., Zheng, Y., & Zhang, P. (2015). Myocardial Infarction: Symptoms and Treatments. Cell Biochemistry And Biophysics, 72(3), pp. 865–867. https://doi.org/10.1007/s12013-015-0553-4
Meszaros, Z. S., Perl, A., & Faraone, S. V. (2012). Psychiatric Symptoms in Systemic Lupus Erythematosus. The Journal of Clinical Psychiatry, 73(07), 993–1001. https://doi.org/10.4088/jcp.11r07425
Murai, K., Sakata, K., Gamou, T., Nagata, Y., Tada, H., Shimojima, M., Okada, H., Hayashi, K., & Kawashiri, M. (2019). Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report. BMC Cardiovascular Disorders, 19(1). https://doi.org/10.1186/s12872-019-1153-9
Niranjan Ojha, & Dhamoon, A. S. (2022). Myocardial Infarction. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537076/
Perry, J. C., Schuetz, T. M., Memon, M. D., Faiz, S., & Cancarevic, I. (2020). Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus, 12(7), e9333. https://doi.org/10.7759/cureus.9333
Reed, G. W., Rossi, J. E., & Cannon, C. P. (2017). Acute myocardial infarction. Lancet (London, England), 389(10065), 197–210. https://doi.org/10.1016/S0140-6736(16)30677-8
Samuelsson, I., Parodis, I., & Anan, C. (2018). PS8:153 Subtypes and location of myocardial infarctions in systemic lupus erythematosus. Poster Session 8: Registries and Cohorts. https://doi.org/10.1136/lupus-2018-abstract.196
Shah, M. A., Shah, A. M., & Krishnan, E. (2009). Poor Outcomes After Acute Myocardial Infarction in Systemic Lupus Erythematosus. The Journal of Rheumatology, 36(3), 570–575. https://doi.org/10.3899/jrheum.080373
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Katus, H. A., Lindahl, B., Morrow, D. A., Clemmensen, P. M., Johanson, P., Hod, H., Underwood, R., Bax, J. J., Bonow, R. O., Pinto, F., Gibbons, R. J., Fox, K. A., Atar, D., & Newby, L. K. (2012). Third universal definition of myocardial infarction. Circulation, 126(16), 2020–2035. https://doi.org/10.1161/CIR.0b013e31826e1058
Tornvall, P., Göransson, A., Ekman, J., & Järnbert-Pettersson, H. (2021). Myocardial Infarction in Systemic Lupus Erythematosus: Incidence and Coronary Angiography Findings. Angiology, 72(5), 459–464. https://doi.org/10.1177/0003319720985337
Nived, O., Ingvarsson, R. F., Jöud, A., Linge, P., Tydén, H., Jönsen, A., & Bengtsson, A. A. (2020). Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus science & medicine, 7(1), e000398. https://doi: 10.1136/lupus-2020-000398
White, H. D., & Chew, D. P. (2008). Acute myocardial infarction. The Lancet, 372(9638), 570–584. https://doi.org/10.1016/S0140-6736(08)61237-4
Zhao, L., Liu, X., Zhang, Y., Liang, X., Ding, Y., Xu, Y., Fang, Z., & Zhang, F. (2016). Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction. Experimental cell research, 344(1), 30–39. https://doi.org/10.1016/j.ye

Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Almothana Aburumman

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.